Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABI-009 in Severe Pulmonary Arterial Hypertension
NCT02587325Phase 1Completed
- Sponsor
- Aadi Bioscience, Inc.
- Start
- Apr 2017
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sirolimus in pulmonary arterial hypertension (PAH) (5 cohorts), sponsored by Aadi Bioscience, Inc. Primary endpoint: Dose-limiting Toxicities at 16 weeks. Started Apr 2017; status: completed.
02
Drugs
sirolimus
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02587325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02587325.